錦欣生殖(01951.HK)根據股份獎勵計劃授出6585.32萬股受限制股份
格隆匯1月19日丨錦欣生殖(01951.HK)發佈公吿,2023年1月18日,董事會已批准根據2022年受限制股份獎勵計劃向承授人授出合共6585.32萬股受限制股份(待承授人接受及其他條件達成後方可作實),其中,(i)2906.1萬股受限制股份授予公司159名僱員,並通過按照計劃規則的條款根據2022年一般授權向受託人發行及配發新股份來實現;及擬將3679.22萬股受限制股份授予5名董事及10名附屬公司董事,並通過按照計劃規則的條款根據特別授權向受託人發行及配發新股份來實現。
公司根據授出將發行及配發的新股份分別相當於該公吿日期已發行股本的約2.4464%及悉數完成上述股份發行及配發後經擴大已發行股本的約2.3880%。經授出後,未來根據2022年受限制股份獎勵計劃可授出的股份數目為937.43萬股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.